The allergic asthma drug omalizumab [`Xolair'; Genentech/Novartis] is expected to cost an average $US10 000 annually when it is launched

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 418, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Psoriasis, prostate cancer drug sales expected to soar

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 323, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Biotech's Biggest Players: Amgen, Biogen and Genentech

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 45-47

Adis International

Access to resources Recommend Favorite

Sales for Krka and Lek, the two largest pharmaceutical companies in Slovenia, rose by 10.2% and 51.9% in 2003 to reach Tol97 billion and Tol145 billion, respectively

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 447, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

The filing for US FDA approval of efalizumab [`Xanelim'; Genentech, XOMA] may be delayed

By  

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite